Showing results (451-460 of 464) with videos related to
Sort By:
Pageof 47
Cancer Drug Resistance (Alhambra, Calif.)|June 13, 2025
Acquired resistance to molecularly targeted therapies for cancerNolan M Stubbs, Tyler J Roady, Maximilian P Schwermann, et al.Oncotarget|September 8, 2016
Discovery and clinical introduction of first-in-class imipridone ONC201Joshua E Allen, C Leah B Kline, Varun V Prabhu, et al.Cancer Research|March 4, 2017
Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical PracticeBernard Leroy, Mandy L Ballinger, Fanny Baran-Marszak, et al.Cell Death and Differentiation|July 16, 2011
Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012L Galluzzi, I Vitale, J M Abrams, et al.Journal for Immunotherapy of Cancer|May 24, 2019
Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administrationMark N Stein, Jyoti Malhotra, Rohinton S Tarapore, et al.Frontiers in Oncology|April 2, 2025
IGV-001 cellular immunotherapy for newly diagnosed glioblastoma: overcoming the logistic challengeEric T Wong, Deus Cielo, Konstantina Svokos, et al.The New England Journal of Medicine|February 22, 2018
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and ChildrenAlexander Drilon, Theodore W Laetsch, Shivaani Kummar, et al.Cancer Biomarkers : Section a of Disease Markers|July 28, 2007
Workshop on imaging science development for cancer prevention and preemptionGary J Kelloff, Daniel C Sullivan, Houston Baker, et al.Cell Death and Differentiation|April 18, 2009
Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotesL Galluzzi, S A Aaronson, J Abrams, et al.Oncotarget|March 12, 2025
Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patientsWafik S El-Deiry, Catherine Bresson, Fanny Wunder, et al.Pageof 47